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Abstract
© 2016 Informa UK Limited, trading as Taylor & Francis Group. Content: Identification of panel
of  SEREX-defined antigens for  breast cancer autoantibodies profile detection.  Objective:  To
create panel of antigens that can differentiate breast cancer patients and healthy individuals.
Methods: SEREX (serological analysis of cDNA expression libraries) method, ELISA (enzyme-
linked immunosorbent assay), qPCR (quantitative polymerase chain reaction). Results: In large-
scale screening of 16 SEREX-antigens by sera of breast cancer patients and healthy donors, a
combination of six antigens (RAD50, PARD3, SPP1, SAP30BP, NY-BR-62 and NY-CO-58) was
identified,  which  can  differentiate  breast  cancer  patients  and  healthy  donors  with  70%
sensitivity and 91% specificity. Elevated mRNA expression of SPP1 gene was revealed in breast
tumors (2–7-fold) that correlated with SPP1 antigen immunoreactivity in autologous patients’
sera. Conclusions: The new panel of six SEREX-antigens was proposed, which enables creation
of serological assay for breast cancer diagnostics and/or prognosis.
http://dx.doi.org/10.1080/1354750X.2016.1252952
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